A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, MulticenterProtocol to Evaluate the Safety and Efficacy of JNJ-64304500 in Subjects with Moderately to Severely Active Crohn's Disease

Trial Profile

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, MulticenterProtocol to Evaluate the Safety and Efficacy of JNJ-64304500 in Subjects with Moderately to Severely Active Crohn's Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs JNJ 64304500 (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms TRIDENT
  • Sponsors Janssen
  • Most Recent Events

    • 14 Sep 2016 Status changed from not yet recruiting to recruiting.
    • 11 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top